申请人:Kasina Laila Innova Pharmaceuticals Private Limited
公开号:US08143237B2
公开(公告)日:2012-03-27
Selenopheno triazene analogs, their compositions, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, and pharmaceutically acceptable salts and mixtures thereof are useful for the treatment of metastatic malignant melanoma and other cancers. The selenopheno triazene analogs have the general formulae (I) or (II):
wherein the substituents R1, R2, R3, R6, and R7 are as described in the specification. Other cancers include which may be treated with these compounds include, but are not limited to, malignant melanoma, leukemia, lymphomas (Hodgkins and non-Hodgkins), sarcomas (Ewing's sarcoma), brain tumors, central nervous system (CNS) metastases, gliomas, carcinomas such as breast cancer, prostate cancer, lung cancer (small cell and non-small cell), colon cancer, pancreatic cancer, Head and Neck cancers and oropharyngeal squamous cell carcinoma.
Selenopheno triazene类似物,它们的组成,互变异构体,立体异构体,多晶体,水合物,溶剂物和药学上可接受的盐以及它们的混合物,可用于治疗转移性恶性黑色素瘤和其他癌症。 Selenopheno triazene类似物具有一般式(I)或(II):其中取代基R1,R2,R3,R6和R7如规范中所述。其他可能使用这些化合物治疗的癌症包括但不限于恶性黑色素瘤,白血病,淋巴瘤(霍奇金氏和非霍奇金氏),肉瘤(尤因肉瘤),脑肿瘤,中枢神经系统(CNS)转移,胶质瘤,如乳腺癌,前列腺癌,肺癌(小细胞和非小细胞),结肠癌,胰腺癌,头颈癌和咽喉鳞状细胞癌。